Lisata Therapeutics, Inc. (NasdaqCM: LSTA)
Health Care · Biotechnology · US
$1.74
+12.26% today · -40.2% 1Y
Lisata Therapeutics, Inc. (NasdaqCM: LSTA) operates in the Biotechnology industry within the Health Care sector. The company is valued at $13.97M and employs 21 people.
Over the last twelve months the share price has lost 40.2%, trading between 0.99 and 5.07.
Tweenvest scores Lisata Therapeutics, Inc. across four factors: quality 38/100, value 55/100. Its strongest factor is value.
LSTA price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $13.97M
- Revenue (TTM)
- $100.00K
- P/E
- —
- EPS
- -1.64
- Dividend yield
- —
- Beta (5Y)
- 0.88
- 52-week high
- $5.07
- 52-week low
- $0.99
- Avg volume (3M)
- —
- Shares outstanding
- 9.01M
- Employees
- 21
- Next earnings
- —
About Lisata Therapeutics, Inc.
Lisata Therapeutics, Inc. is a clinical-stage biopharmaceutical firm focused on pioneering and bringing to market cellular therapies. These treatments are designed to either reverse disease progression or facilitate the repair of damaged bodily tissues. The company's product portfolio features several notable candidates: HONEDRA, which has received SAKIGAKE designation and is presently in Phase II clinical trials for critical limb ischemia; XOWNA, currently undergoing Phase IIb testing for coronary microvascular dysfunction; and CLBS201, a CD34+ cell therapy aimed at individuals with chronic kidney disease who are not yet on dialysis. Founded in 1980 and based in Basking Ridge, New Jersey, the company was initially known as NeoStem, Inc., then rebranded as Caladrius Biosciences, Inc. in June 2015, before assuming its present identity as Lisata Therapeutics, Inc. on September 15, 2022.
- ISIN
- US1280583022
- Founded
- 1980
- Listed since
- Mar 1, 1999
- Exchange
- Nasdaq Capital Market
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $469.68B | $265.79 | +0.48% |
| Amgen Inc.NasdaqGS: AMGN | $239.09B | $442.24 | -0.36% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $184.47B | $148.77 | +1.38% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $140.13B | $552.85 | +0.96% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $83.24B | $833.56 | +0.61% |
| argenx SEENXTBR: ARGX | $64.17B | €894.20 | +1.71% |
| Moderna, Inc.NasdaqGS: MRNA | $63.41B | $158.83 | +14.36% |
| CSL LimitedASX: CSL | $59.49B | AU$173.64 | +2.68% |
Figures last refreshed Aug 18, 2026.